Broadleaf Partners LLC Has $10.50 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Broadleaf Partners LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 27.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,594 shares of the company's stock after selling 5,104 shares during the quarter. Eli Lilly and Company makes up about 2.5% of Broadleaf Partners LLC's portfolio, making the stock its 16th biggest holding. Broadleaf Partners LLC's holdings in Eli Lilly and Company were worth $10,495,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. CWA Asset Management Group LLC raised its position in Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after acquiring an additional 724 shares in the last quarter. Centerpoint Advisory Group acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $514,000. M&T Bank Corp grew its holdings in Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after purchasing an additional 1,867 shares during the period. Kentucky Trust Co acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $834,000. Finally, Proficio Capital Partners LLC raised its stake in Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after buying an additional 1,562 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Citigroup cut their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average target price of $1,017.00.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

LLY stock traded up $4.52 during midday trading on Tuesday, reaching $822.54. 1,510,946 shares of the stock were exchanged, compared to its average volume of 3,772,138. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $779.91 billion, a PE ratio of 70.24, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a fifty day moving average price of $827.99 and a 200 day moving average price of $818.92.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.